Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 Oct. 2];7(2):s134. Available from: https://skin.dermsquared.com/skin/article/view/2004